|
KMID : 1103920130190030273
|
|
Korean Journal of Hepatology
2013 Volume.19 No. 3 p.273 ~ p.279
|
|
|
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
|
|
Kim Jeong-Han
Ko Soon-Young
Choe Won-Hyeok
Kwon So-Young
Lee Chang-Hong
|
|
|
Abstract
|
|
|
Background/Aims:Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to determine the efficacy of this combination therapy in hepatocellular carcinoma (HCC) patients.
Methods:The medical records of CHB patients who developed LAM resistance and were treated with LAM plus ADV combination therapy for more than 6 months were reviewed. Their virological response (VR; undetectable HBV DNA) and biochemical response (BR; alanine aminotransferase normalization) were evaluated, and the findings of HCC and non-HCC patients were compared.
Results:The data from 104 patients (19 with HCC and 85 without HCC) were analyzed. The VR rates did not differ significantly between the HCC and non-HCC groups: 33.3% vs. 55.6% at 12 months (P=0.119), 58.3% vs. 67.2% at 24 months (P=0.742), 50% vs. 69.8% at 36 months (P=0.280), and 66.7% vs. 71.0% at 48 months (P=1.000). The BR rates also did not differ significantly between the groups: 55.6% vs. 84.0% at 12 months (P=0.021), 58.3% vs. 83.8% at 24 months (P=0.057), 70.0% vs. 77.8% at 36 months (P=0.687), and 66.7% vs. 80.6% at 48 months (P=0.591).
Conclusions:The efficacy of LAM plus ADV combination therapy is comparable in HCC and non-HCC patients.
|
|
|
KEYWORD
|
|
|
Chronic hepatitis B, Lamivudine, Adefovir, Resistance, Hepatocellular carcinoma
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|